KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Total Non-Current Liabilities: 2009-2024

Historic Total Non-Current Liabilities for Rigel Pharmaceuticals (RIGL) over the last 15 years, with Dec 2024 value amounting to $120.7 million.

  • Rigel Pharmaceuticals' Total Non-Current Liabilities fell 0.66% to $117.4 million in Q1 2025 from the same period last year, while for Mar 2025 it was $117.4 million, marking a year-over-year decrease of 0.66%. This contributed to the annual value of $120.7 million for FY2024, which is 13.96% up from last year.
  • Rigel Pharmaceuticals' Total Non-Current Liabilities amounted to $120.7 million in FY2024, which was up 13.96% from $105.9 million recorded in FY2023.
  • Rigel Pharmaceuticals' Total Non-Current Liabilities' 5-year high stood at $120.7 million during FY2024, with a 5-year trough of $71.3 million in FY2020.
  • Over the past 3 years, Rigel Pharmaceuticals' median Total Non-Current Liabilities value was $105.9 million (recorded in 2023), while the average stood at $110.8 million.
  • As far as peak fluctuations go, Rigel Pharmaceuticals' Total Non-Current Liabilities dropped by 19.57% in 2020, and later increased by 25.41% in 2022.
  • Over the past 5 years, Rigel Pharmaceuticals' Total Non-Current Liabilities (Yearly) stood at $71.3 million in 2020, then increased by 18.12% to $84.2 million in 2021, then grew by 25.41% to $105.6 million in 2022, then increased by 0.28% to $105.9 million in 2023, then grew by 13.96% to $120.7 million in 2024.